Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VBP
|
|||
| Drug Name |
PMID29053063-Compound-7f
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoglyceride lipase (MAGL) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Monoglyceride lipase (MAGL) | Target's Patent Info | [1] | |
| BioCyc | Triacylglycerol degradation | |||
| KEGG Pathway | Glycerolipid metabolism | |||
| Metabolic pathways | ||||
| Retrograde endocannabinoid signaling | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | Acyl chain remodeling of DAG and TAG | |||
| Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | ||||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| Glycerophospholipid biosynthesis | ||||
| GPCR downstream signaling | ||||
| Effects of PIP2 hydrolysis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.